Bispecific antibodies targeting mutant RAS neoantigens-Reference-Cited by-同舟云学术

Bispecific antibodies targeting mutant RAS neoantigens

Published:2021-03-04 Issue:57 Volume:6 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Douglass Jacqueline¹²³^ORCID,Hsiue Emily Han-Chung¹²³^ORCID,Mog Brian J.¹²³⁴^ORCID,Hwang Michael S.¹²³,DiNapoli Sarah R.¹²³^ORCID,Pearlman Alexander H.¹²³^ORCID,Miller Michelle S.²⁵⁶^ORCID,Wright Katharine M.²⁵⁶^ORCID,Azurmendi P. Aitana²⁵⁶^ORCID,Wang Qing¹²⁷^ORCID,Paul Suman¹²³⁸^ORCID,Schaefer Annika¹²³^ORCID,Skora Andrew D.¹²^ORCID,Molin Marco Dal¹⁹^ORCID,Konig Maximilian F.¹²³¹⁰^ORCID,Liu Qiang¹²³^ORCID,Watson Evangeline¹²³,Li Yana⁵^ORCID,Murphy Michael B.¹¹^ORCID,Pardoll Drew M.⁶⁸^ORCID,Bettegowda Chetan¹³¹²^ORCID,Papadopoulos Nickolas¹³⁶¹³^ORCID,Gabelli Sandra B.⁵⁸¹⁴^ORCID,Kinzler Kenneth W.¹³⁶^ORCID,Vogelstein Bert¹²³⁶¹³^ORCID,Zhou Shibin¹³⁶^ORCID

Affiliation:

1. Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

2. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

3. Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

4. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

5. Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

6. Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.

7. Complete Omics Inc., Baltimore, MD 21227, USA.

8. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

9. Department of Surgery, University of Maryland Medical Center, Baltimore, MD 21201, USA.

10. Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.

11. Cytiva, Marlborough, MA 01752, USA.

12. Department of Neurosurgery, Johns Hopkins University School of Medicine, MD 21205, USA.

13. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

14. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Abstract

Bispecific T cell–engaging antibodies capable of specifically killing cancer cells expressing mutant RAS neoantigens were generated.

Funder

NIH Office of the Director

National Cancer Institute

Commonwealth Fund

Lustgarten Foundation

Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Bloomberg Philanthropies

The Virginia and D.K. Ludwig Fund for Cancer Research

The Mark Foundation for Cancer Research

NIH Cancer Center Support

National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference71 articles.

1. Cancer Genome Landscapes

2. Small molecules, big impact: 20 years of targeted therapy in oncology

3. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

4. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

5. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex;Molecular Therapy;2024-01

2. Review of phage display: A jack-of-all-trades and master of most biomolecule display;International Journal of Biological Macromolecules;2024-01

3. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies;Drugs;2023-12-18

4. Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition;Nature Communications;2023-12-11

5. Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing;Molecular Therapy;2023-12